Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes
Pharma company releases trial data for Technosphere Insulin
January 20th, 2005
MannKind Corporation (NASDAQ:MNKD) released summary information on results from its U.S.-based, late phase 2 clinical study of Technosphere Insulin, a pulmonary insulin formulation delivered via its proprietary inhaler to patients with diabetes mellitus. The MannKind pulmonary insulin system rapidly delivers regular human insulin to the bloodstream in a manner that approximates the first phase insulin release spike by the pancreas that occurs almost immediately after the start of a meal in normal, healthy individuals but is lost in patients who develop diabetes. This spike plays an important role in glucose control by signaling the liver to stop releasing glucose into...
Source: Women's Health Weekly (2005-01-20)
|
